CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Noting the necessary development of treatment centers and the need for more long-term data to encourage greater treatment adoption, I accept that CRISPR stock may not take off for some time. Nonetheless, I remain bullish, given the company's leading position in the gene-editing space. CRISPR Therapeutics: The Opportunity CRISPR Therapeutics has developed life-changing treatments for genetic diseases affecting millions of people worldwide. Its first marketable product, CASGEVY is a gene therapy for sickle cell disease (SCD) and beta-thalassemia, which impacts over 300,000 newborns annually. Not all these people have severe forms of illness, which can be debilitating and disproportionately impact those of African heritage. The treatment employs CRISPR-Cas9 technology to precisely cut DNA at specific locations, allowing the correction of genetic mutations. The CRISPR-based therapy costs around $2.2 million per patient. That might sound expensive, but it's worth noting that SCD-rela
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued." [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $88.00 price target on the stock.MarketBeat
- CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing [Yahoo! Finance]Yahoo! Finance
- Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 5/9/24 - Beat
CRSP
Sec Filings
- 6/24/24 - Form 4
- 6/3/24 - Form 8-K
- 5/31/24 - Form 4
- CRSP's page on the SEC website